CYTK Cytokinetics, Incorporated
$73.77
Cytokinetics, Incorporated (CYTK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Insider signal
In line
Selling ran in line with CYTK's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity
0 buyers in the last 30 days
0 buyers in the last 90 days
6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
10
86 transactions
Purchases
$0
0 shares
Sales
$45.0M
651,668 shares
Net activity
-$45.0M
purchases less sales
How much of that selling was preplanned? 0% planned / 100% discretionary
10b5-1 plan sales
$0
0 transactions · 0 shares
Discretionary sales
$45.0M
86 transactions · 651,668 shares
Largest single sale: $3.5M.
Where they traded
Buy
Sell
Dot area is proportional to transaction value.
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Landry Robert E | Director | Sell | 1,000 | $74.66 | $74.7K | 9,184 −9.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.46 | $264.1K | 153,902 −2.2% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $71.48 | $357.4K | 10,784 −31.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 10,000 | $70.24 | $702.4K | 58,555 −14.6% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.24 | $526.8K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.82 | $265.4K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $76.76 | $575.7K | 377,820 −1.9% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | $79.88 | $1.1M | 58,555 −19.3% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $80.87 | $606.5K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $80.59 | $282.1K | 153,902 −2.2% of holding | |
| Blum Robert I 2 fills | President & CEO | Sell | 7,500 | $82.02 | $615.2K | 377,820 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $86.62 | $303.2K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $85.80 | $1.3M | 58,555 −20.4% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $84.92 | $636.9K | 377,830 −1.9% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 1,112 | $87.79 | $97.6K | 63,221 −1.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 3,134 | $85.00 | $266.4K | 63,221 −4.7% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 38,730 | $82.30 | $3.2M | 63,221 −38% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $79.51 | $278.3K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $70.46 | $528.5K | 385,330 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $67.98 | $237.9K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $74.08 | $1.1M | 58,555 −20.4% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $74.08 | $370.4K | 15,784 −24.1% of holding | |
| Kaye Edward M. MD | Director | Sell | 2,933 | $76.09 | $223.2K | 10,283 −22.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.21 | $579.1K | 392,830 −1.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.69 | $264.9K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $77.92 | $584.4K | 400,330 −1.8% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 23,906 | $76.87 | $1.8M | 63,221 −27.4% of holding | |
| HENDERSON JOHN T | Director | Sell | 20,000 | $75.97 | $1.5M | 75,237 −21% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 11,333 | $77.25 | $875.5K | 58,555 −16.2% of holding | |
| WIERENGA WENDELL | Director | Sell | 4,032 | $75.00 | $302.4K | 32,637 −11% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $77.37 | $270.8K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,857 | $65.00 | $1.0M | 58,555 −21.3% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $63.26 | $948.9K | 58,555 −20.4% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $59.62 | $447.2K | 407,830 −1.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $65.69 | $229.9K | 153,902 −2.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 7,449 | $66.02 | $491.8K | 58,555 −11.3% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $65.38 | $490.4K | 415,330 −1.8% of holding | |
| Malik Fady Ibraham 2 fills | EVP Research & Development | Sell | 4,500 | $65.11 | $293.0K | 153,902 −2.8% of holding | |
| Blum Robert I | President & CEO | Sell | 7,500 | $66.63 | $499.7K | 422,830 −1.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 3,639 | $65.00 | $236.5K | 66,004 −5.2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,930 | $62.07 | $119.8K | 78,185 −2.4% of holding | |
| Blum Robert I 2 fills | President & CEO | Sell | 36,601 | $62.15 | $2.3M | 454,258 −7.5% of holding | |
| Malik Fady Ibraham 2 fills | EVP Research & Development | Sell | 12,033 | $62.15 | $747.9K | 158,299 −7.1% of holding | |
| Callos Andrew 2 fills | EVP, Chief Commercial Officer | Sell | 8,542 | $62.15 | $530.9K | 74,489 −10.3% of holding | |
| Lee Sung | EVP, Chief Financial Officer | Sell | 4,935 | $62.15 | $306.7K | 87,127 −5.4% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,709 | $61.03 | $104.3K | 46,149 −3.6% of holding | |
| Blum Robert I | President & CEO | Sell | 7,931 | $60.72 | $481.6K | 391,673 −2% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,907 | $60.72 | $176.5K | 138,629 −2.1% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 2,582 | $60.72 | $156.8K | 47,858 −5.1% of holding | |
| Callos Andrew 2 fills | EVP, Chief Commercial Officer | Sell | 26,000 | $61.87 | $1.6M | 61,440 −29.7% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $61.21 | $306.1K | 17,933 −21.8% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $61.62 | $54.6K | 50,440 −1.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $61.93 | $929.0K | 50,440 −22.9% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 886 | $62.10 | $55.0K | 50,440 −1.7% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 15,000 | $60.28 | $904.2K | 50,440 −22.9% of holding | |
| Callos Andrew 2 fills | EVP, Chief Commercial Officer | Sell | 1,798 | $62.62 | $112.6K | 50,440 −3.4% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,809 | $62.44 | $113.0K | 51,353 −3.4% of holding | |
| WIERENGA WENDELL | Director | Sell | 20,000 | $66.14 | $1.3M | 32,444 −38.1% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $61.24 | $134.7K | 138,552 −1.6% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 1,042 | $65.96 | $68.7K | 50,660 −2% of holding | |
| Callos Andrew | EVP, Chief Commercial Officer | Sell | 52,486 | $65.95 | $3.5M | 50,660 −50.9% of holding | |
| HENDERSON JOHN T | Director | Sell | 8,750 | $63.90 | $559.1K | 74,578 −10.5% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $63.89 | $140.6K | 140,610 −1.5% of holding | |
| Kaye Edward M. MD | Director | Sell | 28,064 | $66.72 | $1.9M | 9,977 −73.8% of holding | |
| Harrington Robert Arthur | Director | Sell | 2,150 | $66.80 | $143.6K | 18,542 −10.4% of holding | |
| PARSHALL B LYNNE | Director | Sell | 5,000 | $64.73 | $323.7K | 22,933 −17.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,200 | $66.45 | $146.2K | 140,610 −1.5% of holding | |
| Kaye Edward M. MD | Director | Sell | 5,175 | $65.08 | $336.8K | 9,977 −34.2% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,295 | $59.55 | $136.7K | 140,610 −1.6% of holding | |
| Blum Robert I | President & CEO | Sell | 5,000 | $62.86 | $314.3K | 358,108 −1.4% of holding | |
| WIERENGA WENDELL | Director | Sell | 4,375 | $58.68 | $256.7K | 32,444 −11.9% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,105 | $58.22 | $122.6K | 140,610 −1.5% of holding | |
| Blum Robert I | President & CEO | Sell | 5,000 | $60.03 | $300.2K | 363,108 −1.4% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $60.56 | $121.1K | 140,610 −1.4% of holding | |
| Kaye Edward M. MD | Director | Sell | 6,757 | $60.00 | $405.4K | 9,778 −40.9% of holding | |
| Blum Robert I | President & CEO | Sell | 5,000 | $55.05 | $275.3K | 368,108 −1.3% of holding | |
| Kaye Edward M. MD | Director | Sell | 6,695 | $55.08 | $368.8K | 16,535 −28.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 2,000 | $49.28 | $98.6K | 140,610 −1.4% of holding | |
| Blum Robert I | President & CEO | Sell | 5,000 | $49.77 | $248.9K | 373,108 −1.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.